Podcasts about Cart

When a once-reliable podcast promo email suddenly tanks to 15% opens, you either keep pretending it's fine or you blow it up and rebuild it from scratch. You'll hear Jay Schwedelson and Amy Porterfield get honest about what changed in her newsletter, why “being more you” is now a real growth strategy, and how to experiment without freaking out when people unsubscribe.ㅤSubscribe to Amy Porterfield's newsletter, listen to The Amy Porterfield Show, and follow her on Instagram.ㅤBest Moments:(03:45) When 15% open rates forced a total newsletter reset.(05:03) Why letting your real personality show matters even more in the AI era.(07:06) Turning “YOUR cringe” feedback into a subject line that popped open rates.(08:06) The email metrics she still watches, and why beating your own baseline is the point.(13:10) Cart-close urgency is shifting, so she frontloads webinars in the first 48 hours.(17:12) The custom AI tool move that makes “just use ChatGPT” the wrong answer.ㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/

“Your beliefs govern your reality.” In this episode, Nick speaks with Damon Cart, an NLP teacher and coach, about the transformative power of self-concept coaching. Damon shares his personal journey through depression, the importance of understanding one’s values, and the pitfalls of self-worth. What to listen for: Understanding your values changes how you approach achievement Self-worth is a flawed concept; it’s better to focus on values instead Taking action is crucial for gaining clarity on what truly matters Failure can lead to unexpected success “It has everything to do with your beliefs… Most people don’t believe they are the value that they’re seeking.” When you don't see your own value, you'll constantly search for it outside yourself Confidence and self-esteem are built internally, not earned through achievements Changing your beliefs about who you are opens the door to the life you actually want “If you’re adamant about being a happy and fulfilled person and you’re willing to work for it, you will get there.” You're never permanently stuck unless you stop moving toward what you want Working on yourself is an investment that pays off in how you experience life Happiness grows when you treat it like a priority, not a side quest About Damon Cart Damon is a world-leading expert in creating lasting internal transformations using the Self-Concept model™. As a master NLP practitioner and co-founder of The Self-Concept Research Group, he transformed his own life from a struggling insurance agent to a globally recognized authority in personal development. Mentored by NLP pioneer Steve Andreas, he has spent nearly eight years helping thousands achieve identity-level change. Based in Santa Cruz, California, Damon combines deep theory with practical application to make transformation effortless and permanent. https://selfconcept.com/ https://www.linkedin.com/in/damon-cart-aa79b122/ https://www.instagram.com/damoncart Resources: Interested in starting your own podcast or need help with one you already have? Send Nick an email or schedule a time to discuss your podcast today! https://themindsetandselfmasteryshow.com/podcasting-services/ Thank you for listening! Please subscribe on iTunes and give us a 5-Star review! https://podcasts.apple.com/us/podcast/the-mindset-and-self-mastery-show/id1604262089 Listen to other episodes here: https://themindsetandselfmasteryshow.com/ Watch Clips and highlights: https://www.youtube.com/channel/UCk1tCM7KTe3hrq_-UAa6GHA Guest Inquiries right here: podcasts@themindsetandselfmasteryshow.com Your Friends at “The Mindset & Self-Mastery Show” Click Here To View The Episode Transcript Nick McGowan (00:01.436)Hello and welcome to the Mindset and Self Mastery Show. I’m your host, Nick McGowan. Today on the show we have Damon Cart. Damon, how you doing today? Damon Cart (00:11.266)Good. How are you? Nick McGowan (00:12.828)I’m good, man, I’m excited. As I told you, this is the first episode of Brand New Office. So if people watch the video and I’m looking around, it’s other stuff in the office. I’m excited that you’re here, man. We were just shooting the breeze a bit before we got started and I’m excited to get into things. So why don’t you kick us off? Tell us what you do for a living and what’s one thing most people don’t know about you that’s maybe a little odd or bizarre. Damon Cart (00:23.182)you Damon Cart (00:35.694)Hmm. Well, I teach NLP and I coach it as well. I do one-on-one coaching and not just NLP. I focus on a specific model called the self concept model. And it was a model that was taught to me by my mentor, Steve Andreas. He created it. And it is a model that models our identity, how we create our sense of self and how to transform that. Most people are not living the life that they would want to be living. And that’s rooted in them not being the person they want to be. And we think that we have to go conquer mountains or defeat dragons until we’re worthy of that. And that’s just not true. It has everything to do with your beliefs and how you organize that information into those beliefs and what in fact you believe about yourself. And most people don’t believe they are the value that they’re seeking. And as a result of that, they experience lower self-esteem, lower confidence and overall just lack of fulfillment. And we can transform that and sometimes as simple as one hour session just by transforming beliefs, restructuring that information. So instead of taking years of willpower and discipline and all of those things, it’s really in how you think about it. And there’s an exact organization to that. And once you understand it, then you can change it. And something about me that is, I don’t know if I’m, I don’t know, I feel like I’m a pretty open book about things, about myself. And I don’t know of anything that I would call bizarre. would say something that probably not a lot of people know about me, unless you really know me very well, is that I’m a rather emotional person. And that can be anything. That can be anger. That can be watching a movie and, you know, feeling emotional because of it, because it’s sad or it’s a great love story or something like that. I tend to be very emotional and be The older I’ve gotten, the more comfortable I am with just being emotional and vulnerable in front of people. But I don’t really show that in my videos. In my persona online, it’s just not, I don’t think it’s really relevant. And it’s not that I’m ashamed of it. It’s just, I don’t see the value in doing that. I’m a teacher and it’s for me, it’s about getting the information out there. Nick McGowan (02:51.884)Interesting. I want to go down that path a little bit because I am emotional. If you watched any videos, you can see some of the emotions come out. There are often times I’ll blame, I’m from Philly, so I’ll just blame the Northeast. I’m like, it’s because of Philly. Like, yeah, yeah. And that’s what everybody thinks about Philly people anyway. They’re crazy or they’re loud. It’s like partially, but some of that’s also generational trauma and they don’t really know how to handle it. And Damon Cart (03:03.854)Why not? Nick McGowan (03:16.787)It’s interesting because also as we get older like you can watch a commercial and you get over 40 and you start crying and you’re like I don’t know why like what the fuck was that what a good 12 second clip of something but it’s interesting that you put that to the side when you make your videos and it sounds really conscious like you’re like I’m not gonna allow myself to be not vulnerable but emotional because you don’t want it to block the message is that about right? Damon Cart (03:43.691)You know, got a comment on one of my videos recently and that one of the live streams I did was very academic. And I was like, well, like as opposed to what, how do you, because they’re, and you’ll hear people throw this word around when it comes to NLP teachers. like, this person’s very academic. And to me, that means like more theory-based and not experiential, but NLP is very experiential. So I was just like, well, you know, how do, Nick McGowan (04:03.638)Mm-hmm. Damon Cart (04:09.358)As opposed to what I’m giving you the steps of a process that you have to go and do and experience and he was like no No, not like that. You should put your personality into your videos more and he referenced a podcast and I went and looked at the podcast and it was one of those kind like bro podcasts where It was a young man and he’s you know, kind of putting a little bit of arrogance out there No judgment on him. Like this is what plays this is what sells and So I haven’t responded to the person yet, but on my video, but basically it comes down to this I I don’t see myself as the brand of what I’m doing. The information that I’m getting out there is the star of the show, not me. And there have been times where I put my personal life on there. I’ve done vlogs and things like that. And you will see me get emotional in those. But I’ve never found it to be like why people are coming to my videos. And if my personality overshadows what I’m teaching, which is you see this in like Tony Robbins, you know, and Nick McGowan (04:46.008)Mm. Nick McGowan (05:06.915)Yeah. Damon Cart (05:06.926)Then I feel like I’m not doing my job. I feel like I’ve the message and what I’m teaching is the most important thing, not who I am. I don’t want my, if I get emotional about something, I don’t want that to hijack the video. I want the information I’m teaching to be the thing that people are coming for and that they’re getting it. Nick McGowan (05:20.653)Yeah. Nick McGowan (05:26.553)That makes total sense. And I guess to people that don’t know that, they’re just going to interpret how they’re going to interpret because we are people and we’ll interpret things how we want and make up a story and go, here’s what it is. But that’s a great way to put it. You’re stewarding it. You’re basically just letting it come through you and kind of work through you. Do you feel like some of it is also channeled in that sort of way specifically? Or are you just saying, I’ve learned this information. I want to package it in the right way so you can get the information and Damon Cart (05:38.466)Yeah. Damon Cart (05:41.826)Yes. Nick McGowan (05:56.342)Never mind how I feel about Damon Cart (05:58.735)So definitely yes to the second part, when you say channel, what do mean by channel? Nick McGowan (06:04.412)There are certain people that channel information from a higher level, from God or from the universe or whatever, and they feel that comes through them. It’s almost like how creatives or artists can say, I don’t really know where that came from, but it just came out of me and it was kind of channeled through. And I’ve seen different people and I’ve talked to different people that are like, I don’t let my vessel really, or like the being get in the way because it’s being channeled through. And it sounds like you’re taking more of the conscious approach of like the information is the information. So take the information and me being yelly or emotional about it or whatever is not going to do you a bit of good. Here’s the information. But it also sounds like that person who’s like, I want I want you to be emotional because they probably are, you know. Damon Cart (06:46.668)Yeah, and yeah, so I’ve had those moments on, because I like to do live streams. So yeah, I’ve had those moments where I felt like, yeah, I was just channeling. But majority of it is, I’ve felt this my entire life. If I was struggling to solve a problem and I solve that problem, I know that there are other people who are trying to solve that problem and they’re really frustrated. And I know what that frustration feels like. So I just want to go to them and say, here’s the key or here’s. Here’s the information you need so that you don’t need to struggle with this anymore. And I feel like that’s really my job. My channel started with one of the things I realized very quickly when I was going to like one NLP training after another, especially getting into more and more advanced NLP trainings that I was attending, not teaching, was how many people didn’t actually know basic NLP. And it was like, okay, they’re spending thousands of dollars learning all this. And it is true. Like you just don’t really get a lot of practice in NLP trainings because that would make Nick McGowan (07:34.966)Mm. Damon Cart (07:43.299)the training’s extremely long and that wouldn’t be very competitive in the market. So people aren’t really practicing and then they hand you a certificate and say, now you’re certified. And it’s like that is completely meaningless. You have to go and practice it. And so what I was doing is I was practicing every single day on myself. was practicing, I had a practice group and I would practice with them once a week and had a practice partner who I practiced with once a week. And I was practicing on people and they didn’t even realize it. I was just making the world my NLP classroom. Nick McGowan (07:44.983)Yeah. Damon Cart (08:11.054)So I was understanding NLP rapidly. And a lot of this, was not getting the help of a teacher or a mentor up until I met my mentor, Steve Andreas. And so I started my YouTube channel being that the whole point of it was I’m going to teach people what they should have learned in their NLP training. And actually to this day, when I’m going, when I’m speaking at conferences, actually when I’m shoulder to shoulder speaking with other people who are presenting at these conferences, they will come to me and say, When I was taking my NLP training, I didn’t understand what I was learning and I had to turn to your videos because your videos were the videos that actually taught me what I was supposed to know. And so I get this compliment to this day, which is a huge compliment because that’s exactly what I was set out to do in the beginning. So yeah, I’ve always, the spotlight has always been the information that I’m teaching, not me. Nick McGowan (08:46.155)Nice. Nick McGowan (08:59.383)And it sounds like with everything you’re saying, you’ve just solidified it more and more and more. Like if they were like, you know, it’s a little dry, you would probably open up a little bit in that sort of way. But the fact that you keep getting like, this is what you set out to do and this is what it’s about. That’s awesome, man. And again, I think people are gonna interpret how they want. Like I wanna hear more emotions. Damon Cart (09:17.378)Yeah, and I do share, I’m happy to share like one of the reasons why I’ve had a lot of people come to me for coaching is they would say like, you know, I heard some of what you were saying and it didn’t really speak to me, but when you talked about your depressions or you talked about your divorce and things like that. that is something that I think it helps feed what I’m trying to do here. When I, when I don’t pretend like I’m this perfect person, I think when people are trying to really build a personality brand, that’s what they’re doing. Nick McGowan (09:30.69)yeah. Damon Cart (09:45.133)And there are people who want to follow that. want to believe that there are these sort of like higher than human people that they can follow. I just, that defeats the whole point. So yeah, I want people to know that I’ve worked through problems. I’ve worked through depression. I’ve had a divorce. I’ve had to deal with, you know, trying to maintain relationships with my kids. Nick McGowan (09:45.216)Yeah. Nick McGowan (09:55.851)Yeah. Damon Cart (10:06.222)you know, in these tough times of going through a divorce and moving out of the home, you know. So I do talk about these things because I want people to understand that I’m not just like coming from a place of like, had this all figured out from the beginning. It’s like, what I’m giving you is things that, problems that I’ve solved, things that I had to figure out for myself. that’s how I know that it works. And so now I’m giving it to you. So you don’t have to stay in that frustration. Nick McGowan (10:18.443)haha Nick McGowan (10:31.273)Wait, so there aren’t perfect people on the planet? Like there’s not somebody wandering around? Like all these people on social media? Damon Cart (10:36.426)you would be amazed you would be amazed at how people really buy into that stuff and i just like yeah Nick McGowan (10:41.716)my God, well they want to, you know? Like they really want that. And I can understand like really wanting that, but it’s like self-awareness. Like once you see it, like you can’t not see things. So if you’re like, I want this, why would I want this? Well, you know, and then you kind of work through your stuff. But big thing you’re saying with this is context. Like setting the stage, giving some context to it. Like if you just talked about all these things and you’re like, went through a divorce, but I’m totally good. And like everything’s totally fine. And like everything’s all right. for the people that are out there that would just be like, cool, see, he’s totally good. Like you’re actually hurting those people at that point. And it’s interesting, cause I think there’s a lot of like, there’s a lot of hurt that’s being given out from coaches because they’re not actually working through this stuff that they’re working through. You told me before we even got started, like you were doing the work and kind of almost tripped into this because it made sense to do it when it made sense instead of like where I think 2020 and the whole COVID thing is an easy thing to look back to because a lot of people were like, well, what the fuck do I do now? I guess I become a coach for what? I don’t fucking know. But I guess I’ll do it because I see these other people doing it and like, why the fuck not? And at that point, they’re just like spewing things. I kind of tripped backwards into coaching because I went through a divorce and I had friends that were like, man, you helped me. Can you help a buddy of mine who’s also going through shit? Can you help somebody else? And it’s like Damon Cart (11:46.635)Yeah. Nick McGowan (12:05.334)Yeah, but I need to do so much more work because the more that you learn, the more you understand. Like there’s more to know about it. And likewise, I’m sure with the NLP stuff, like as you started to go into it, I’m sure you got three weeks, three months, three years into it. You’re like, oh my God, there’s so much that I’ve learned from it that you’re then able to turn around. And it sounds like you’ve got a good, I guess mindset, a sense of like, I’m going to help. I want to deliver the information instead of like pushing it upon people. But why don’t we take a little bit of a step back. How the hell did you get here? I know a little bit of the story, but why don’t you share that? Because again, context is important. Damon Cart (12:40.153)Yeah, so I became, well, I had my first depression right after I graduated college and it was, 9-11 happened. It was the first time I was out of school in my entire life. I guess I started going to school like at three and now I’m like 22 and I’m out of school for the first time and just, you know, facing that the rest of your life. Like, what do I do now? Nick McGowan (13:06.409)Yeah. Damon Cart (13:06.734)Yeah, 9-11 happened, which really shook me up because you feel like you’re living, you don’t even question your safety and suddenly something like that happens. And then I got arrested for something really stupid. And it’s really stupid to the point where it’s like, I mean, if you want to get into it, I don’t mind talking about it, but it’s not, I don’t know, I don’t find it that relevant. anyway, those three things happened in one summer. And I just was like, I don’t even feel like walking out my front door. It just feels dangerous. Like, who knows what can happen? Nick McGowan (13:22.1)I’m down. Nick McGowan (13:26.206)Fair enough. Damon Cart (13:35.047)And I gradually just kind of like pulled in more and more and didn’t process the feelings, the negative feelings that I was experiencing. And I just suddenly I realized I’m in a really bad place. And I’ve actually been in this place for months now. And I don’t know how to get myself out of it. And I remembered that I had a professor who taught a class called the philosophy of psychology. And he went through different therapeutic modalities, including hypnosis and gestalt therapy, which NLP is based on. And then at the end, he Nick McGowan (13:57.267)Mm. Damon Cart (14:04.856)pulled out NLP and he said like, this is the mother of them all, because it takes the best of everything that whatever works. And I was just amazed by what this guy could do. And I was, I remember thinking to myself, I got to learn this NLP thing one day. So that was in college and then I was graduated. Now I’m experiencing depression. I don’t have health insurance. I’m a bartender. And so I can’t, I don’t even have the money to hire a therapist. Nick McGowan (14:16.2)Mm. Damon Cart (14:27.502)So I remembered my professor and I called him up and told him what was going on and he said, well, come into my office. He said, I don’t believe in a free service, but I also don’t need your money. So he said, donate your time every time you come to see me to charity or money or whatever. And he’s like, I’m not going to check back with you. I’m just going to trust that you do it. Come back next week and we’ll get to work. I come back next week and in one hour session, months of depression is gone. And I just, my logical mind said, no, no. Nick McGowan (14:45.971)That’s cool. Damon Cart (14:57.056)No, cannot even be possible. But every other part of me was just like, I’m free, like I’m not depressed anymore. And I remember leaving his office and just like I had to stop and sit at a bench on the campus and was just like looking around. like, I walked in there a different person. I walked in there depressed and I’m walking out and there is no depression. just didn’t, it seemed crazy. And so I didn’t get depressed for another 10 years. And when I finally got depressed again, it had nothing to do with what I had gotten depressed with the first time. Nick McGowan (14:58.13)Hehehehe Nick McGowan (15:19.816)Yeah. Damon Cart (15:26.926)But I can say now, knowing NLP, that it was a way that I would think about things. Depression is a process, not like a thing. So, you know, 10 years later, now I’m living in Santa Cruz, California. I have an insurance agency. I’m married and I have two really young kids, like two kids under two years old. And everything is going wrong. And so I slip into a depression again and then even realize it. My wife at the time, ex-wife now, she’s a therapist and she just said, you need help. And I remember Part of me was like well, no, don’t and then I just stopped and I was like, yeah, actually I do I’m not good. And so I found a therapist and this was traditional therapy So I went to traditional psychotherapy and it took me an entire year to come out of depression So we’re talking one session with somebody who knew NLP versus an entire year with someone who’s doing more traditional therapy And when I started to realize even though I was out of that depression I was thinking maybe I can make some progress and some advances here But no, he only knew how to get, this therapist only knew how to get you out of the hole. And then once you were there, then he kind of like kept you there by asking more and more about problems rather than trying to move you to solutions. And I was like, okay, this isn’t working for me anymore. And so I stopped going to see him, but I knew if I didn’t do something different, I was going to end up right back there again. And that’s when I decided it’s time to learn NLP. And there was a training that might still happen here in Santa Cruz where NLP was created up at the university every summer. Nick McGowan (16:31.538)Mm. Damon Cart (16:56.52)And so I went to that training and it just felt like I came home. I was like, this is what I’ve been looking for. And I wasn’t even thinking that I was going to be a teacher or a coach at that point. I was still thinking I’m going to fix my insurance agency and I’m going to fix my marriage and everything’s going to be great. And I just couldn’t stop doing NLP. I would just try to get into a training every chance that I could. Like I mentioned before, I was practicing all the time. And by the time I came back a year later, Nick McGowan (17:00.627)Hmm. Damon Cart (17:22.79)About 75 % of the people who were there the year before returned for the, it was a master practitioner training. And they just kept coming up to me and they were like, why are you so much better than us? And I was like, I don’t know. said, so I started asking them questions and they were like, you we went, we got the same certification you did. So we, you know, we should be at the same level as you. And I was like, did you practice? Have you practiced at all since the last training a year ago? And they were all no. Nick McGowan (17:28.528)Well. Damon Cart (17:51.343)I was like, it’s not a secret. If you don’t practice, you’re not going to get good at it. And that’s why I’m better than you is I’m not, I don’t have any special talents. just practice. And, uh, so, and that’s when people started saying, uh, and then when I go to other NLP trainings, people would be like, well, how long have you been a coach or how long have you been a teacher? And I was like, I’m not, I’m an insurance agent. And they were like, what are you doing here? Cause mostly coaches and you know, teachers go to these trainings. And, uh, so yeah, by that point, after a year had passed, I was like, yes, I’m going to. Nick McGowan (17:53.212)Yeah. Damon Cart (18:20.216)I’m coaching, I’m gonna do teaching. And even still, was more about I wanted to be better at NLP and that was was driving me to wanna do that. So I started just teaching workshops and when that didn’t go very far, that’s when I decided to get on YouTube. A friend of mine actually said, hey, you’ve been to film school, why don’t you try YouTube? And so like, okay, I’ll give that a shot and I did. And yeah, I realized in that whole process that my marriage was not salvageable. was… just, you know, we hit that inroads and it was nothing that was going to make it better. And I also realized that being an insurance agent was making me absolutely miserable and there was no changing that. So it was like, you know, it’s not, I always thought that it was something about me not being good enough. And that’s why I wasn’t succeeding at the insurance business, but it was like, no, it’s just not a good fit. The crazy thing about it, once I realized that, and I realized that it was just going to use the business to keep me afloat until I transferred into this other business. I actually was able to make it successful at that point. was really strange. It’s like when, you know, this thing you’re trying so hard to do and then you finally say, fuck it, I don’t care anymore. Then it, you know, then it was easy. And then it was like, I want to say it easy, but it was, it was working a lot better. And so I was just basically, I moved my office in with another agent. said, can you babysit this while I transition out of this? And he said, yeah, absolutely. And so I was, you know, it took me a few years to kind of figure out this new business. But once I did, I was, I jumped and haven’t looked back since. Nick McGowan (19:20.817)the Yeah. Nick McGowan (19:46.162)I love all that and especially the I mean the real side of it like I joked like yeah You were overnight success took nine years like the amount of stuff that people see that they think like this is Whatever they make it up to be in their own heads and the fact that you were doing the work I mean there are little principles that are through all of this stuff where it’s like You did it in the sense that you just wanted to learn it and you were you even said to me that it was your calling When we feel that and we go in that direction, things will start to get easier, even if it’s the other stuff of like, I need to get this away. And I don’t know the answer to this question, but is it safe to assume that you’re living a better life and more happy life than you did when you had the agency, when you were married, at least to her and like where things are now, is it better? Damon Cart (20:33.742)100 times over. Especially thinking back during the times that I was depressed and I was just like, I guess this is just kind of how life is going to be for the rest of it. And that was depressing to even think about. And that’s what I like to tell people because when I come across someone who’s either depressed or kind of close to that. I want to be respectful. You don’t want to just say, your life is so much better than you. That will make it worse. what I do want to communicate to them is it will get better. It can get better. If you’re adamant about being a happy and fulfilled person and you’re willing to work for it, you will get there. You’re not stuck. This is not how the rest of your life has to be. Nick McGowan (21:02.095)Yeah. Damon Cart (21:25.708)Because yeah, like at this point, it’s like it has exceeded the fulfillment I experienced now has exceeded what I thought was even possible. And still it’s getting more and more fulfilling. So my take on it now is just like, well, how, how good can this get? How deep can I take this? And it’s not like a, it’s not like a greedy thing. It’s more of like a potential thing. What potential do I have to be even more fulfilled and Nick McGowan (21:43.877)Yeah. Damon Cart (21:52.844)more engaged in life and I’m curious to see how far I can take that. Nick McGowan (21:58.124)What a cool aspect of it. Like, well, fuck, let’s see what happens. And like, cool, let’s see how far we can go. And I think to call something out here too, for the people that are listening, isn’t, Damon’s not saying like, well, I was in a shitty spot. I learned this thing and everything worked better. Like that’s just not how life works. Like the amount of work that you had to put in that wasn’t just like curriculum work, but also work on your own. if you… Damon Cart (22:01.698)Yeah. Nick McGowan (22:26.232)If you actually sat back and thought about the amount of hours that you spent just even pondering on it, thinking about it, looking at other people, how they relate to life and what they do. Like you literally enveloped yourself in it instead of saying, well, I really want that. And the reason why I say that is there are people that I hear from the times that are like, man, I’ve tried therapy. I’ve tried this. I’ve tried that. It’s like, great. So what’s next? I’m like, if that didn’t work or if that was a piece of it, like talk therapy, everybody will go into talk therapy and they’re like, This was great and it led me in some direction or it was bullshit and I just yammered to somebody about my problems and they were, they would ask me, how does that make you feel or whatever? It’s like, that’s a part of all of this, but not just the end thing. I think a lot of people do want, they just want that like, what’s the pill that I can swallow and like push all this stuff away instead of trying to break down one barrier to break down another, to break down another, like they’re. There are visuals in my head at times where I’ll climb a mountain only to get to the top of it and go, what the fuck is that? Jeez, it’s another, all right, cool. And you get to a point where you just, you keep trucking along with it. So let’s talk about some of the really tough times where obviously going through a divorce can be a tough time. And for somebody who’s a divorced, it’s one of those things like congratulations or I’m sorry, or a mixture of both, you know? But that can be one of those things that really shapes you in a beautiful way. Like I used to tell people, Damon Cart (23:44.2)All right. Nick McGowan (23:51.65)I didn’t get a divorce to die. I got a divorce so I could live and actually change things. like, I look at life now and think, my God, how did I have that same sort of question that you did of like, well, is this it? I guess this is it. So I guess this is just what life is gonna be like. And it doesn’t have to be that way, but there were still dark times he went through. So were there any that come to mind that you were like, man, that was one of those like super pivotal moments? Like I went through that within my NLP journey and that changed how things shifted. Damon Cart (24:23.212)Yeah, there were a few. When I got a divorce, I was dating for the first time in 15 years. And in my late 30s, that was scary. Things had changed quite a bit. Now there was online dating, and I tried that. And that didn’t go so well, because on these apps, it’s like 70 % men and 30 % women. So the odds are really stacked against you. So I also had my own business, so I wasn’t going to date my employees nor my insurance clients. so I started saying, realizing that I needed, if I saw an attractive woman, I was going to have to go and just talk to her, you know, and that was really difficult to do. And also wanted that choice because I was kept slipping in the relationships, even some of the rebound relationships that I went through, kept slipping in the relationships where the women would turn out to be very passive aggressive and playing a lot of games and really trying to control and manipulate me. And I remember coming to like a choice point thinking, wait, Nick McGowan (25:16.247)Mm. Damon Cart (25:23.126)Is this all women are all women like this or is this just the women I’m attracting? And so I had to be really like honest with myself and I was like, you know what? I’m going to take this on. This is my responsibility. I know that there are good women out there. And so there’s something I’m doing that’s attracting this type of woman. And I want to figure out what that is. And so I just decided I was going to just date and date and date for an entire year. And at the end of that year, if I found someone that I was going to settle down with them. And I did find someone and it was coming up to that year and then the red flag went up and I saw she was doing the same thing. And I was like, oh man, I spent a year doing this and I almost missed it again, almost got slipped into this relationship with this person who was basically going to, it was going to be a rerun of all my relationships. And so was like, I need another year. And so I went another year and I dated a lot. could catch these red flags very quickly. Nick McGowan (26:01.954)Hmm. Damon Cart (26:16.366)And I started realizing that I was putting a certain kind of vulnerability out too early and certain women, was attracting certain women because they thought that they could control me. But once I made it clear that I understood what they were doing, because the last thing a passive aggressive person wants is to be called out. That’s why it’s passive aggressive, right? So I would start calling out what they were doing. They would disappear very quickly. And then I started to develop myself along that way and started attracting much better women. But I do remember like, I was getting to the end of like, Nick McGowan (26:24.066)Yeah. Nick McGowan (26:30.517)Yeah. Damon Cart (26:46.178)I was getting into the third year and I was like, I’m not really finding anyone. was just, I was really getting a bit cynical about it. And I just thought maybe I’m not gonna find someone to share the rest of my life with. And so I quit dating for six months. Like I quit approaching, quit dating. And I was just like, I really needed to focus on my business. Cause that was something that was lacking as well. And I had another big failure in that. Nick McGowan (26:51.243)Hmm. Damon Cart (27:11.756)that I was able to overcome. I was like, you know, less dating, more attention on my business. And that started to work out well for me. And six months later, I had like zero social life. I hadn’t been on a date in, you know, six months. And I was like, OK, I was just finishing up this online training that I had created. I was like, I really need to get out. I need some sunlight. I need some fresh air and I need to see people. And I’m walking down the street downtown here in Santa Cruz. And I just see this really attractive. really young woman and I was trying to talk myself out of talking to her but I was like you know actually no I’m gonna go do this and I just walked up to her and told her I thought you know she was really cute and that I wanted to know her name and possibly go out on a date with her now I’m married to her and you think about those times where you know you almost didn’t do something but you did and then how that changes the trajectory of your life And then that opened a whole new can of worms because she’s from a different country and we got separated by COVID. And she also got her visa taken away. we basically, we eloped in Istanbul, Turkey. The media picked it up and so it was broadcast live in Turkey, our wedding. And then we still couldn’t be together. And so it went on for two more years where the only way we could be together is if I traveled to Romania or we traveled to a country where we could both enter. It was a… Nick McGowan (28:37.42)Mm. Damon Cart (28:38.508)That was another dark time, but with a light at the end of the tunnel. but yeah, that’s, I threw a lot in there all at once. And I also, another dark time was a time that, I, my, business that I have now, had a major failure. And I just thought that was the end of it. All this work that I had done on YouTube for, you a year of doing videos. did a video every single day for eight months straight. And that was a lot of work. And I, that’s how I started to build. Nick McGowan (28:45.366)pain. Damon Cart (29:07.232)my following and then I put out my first training after doing youtube and it just was a spectacular failure and I thought that’s the end of it all this work that I had done and six weeks of I didn’t publish a single video and for six weeks and then suddenly I started getting all these emails and these messages hey we haven’t seen you put a video out in a while we’re worried about you are you sick are you dead let us know you’re okay and I was like you wouldn’t come to my Nick McGowan (29:30.154)Thank What? Yeah. Damon Cart (29:35.235)fucking training and you just want me to keep putting free videos out there. Is that what this is about? So was a little resentful, but then I started making videos again. And then I realized what that was all about. It was, I was promoting a live in-person workshop for a different trainer. And it was like, they, my following didn’t know who he was and didn’t want to see him and didn’t want to show up to a live workshop. They wanted on, they found me on a screen. They wanted me and they wanted me on a screen. And that’s when I realized. Nick McGowan (29:41.654)Yeah. Damon Cart (30:02.734)that they wanted digital products, digital trainings. And so I didn’t know that at the time, but I just thought nobody really wants to know what I have to say and that’s the end of it and it’s time to go move on to a different business. It was quite a relief when I realized the mistakes that I’d made and that actually people did want what I was offering. yeah, so it was a interesting learning curve and very frustrating at the time, but it all ended up being really good. Nick McGowan (30:31.084)So in what was that five minutes seven minutes, maybe you’ve just chunked all this stuff in and I I laugh at times because I think it’s funny how we can we can look in like history books and they’re like from this period to this period like 600 years these three things happened. What the fuck do you mean? Like there were so many other things that happened. You had all these dark times even the six weeks off. I’m sure you still had the body feeling of like why I got to sit down. I could do the video. Wait a minute. And then people come back, be like, are you all right? Are you dead? And be like, what the fuck do you mean? Where have you been? And you’re like… Damon Cart (31:04.15)No, and was so cliche, like whenever that failure happened, had trouble getting out of bed. I stayed in my pajamas most of the day. All the blinds were closed. They had very little light in my apartment. it’s like, because it was so weird. Like, I look back on it now, but it was like, that’s what you would see in a movie because you have to like show, you know, what’s going on inside the character by lighting it the right way and all that. And it was like, that’s what I was actually living through. And I didn’t even realize it at the time, but I was like, yeah, it was a Nick McGowan (31:24.479)Yeah. Damon Cart (31:33.773)It was a dark time and it was literally dark in my home. And that’s the way that it all felt. And finally, I remember just kind of emerging from that. And it was almost like opening the blinds and letting the sunlight in. it was like, you know what, I’m going to pick up my camera. And, yeah, I was just like, you know what? I’m a teacher. This is what I do. So I’m going to put that camera back up and start teaching again. And then eventually shortly thereafter, it led to one of the biggest successes that I had that still creating a training that I’m. Nick McGowan (31:37.685)Yeah. Nick McGowan (31:45.215)Bird singing. Damon Cart (32:02.956)you know, still selling to this day because I put so much effort into it. And, but if it hadn’t been for that failure, I would have never discovered that. And so, you know, it’s how these things often work. Nick McGowan (32:14.994)It’s how life works. Like you have to fail through things. You have to fuck around and find out. You also have to bash your head into the wall, the wrong wall sometimes to go, well, shit, that’s the wrong direction. Let me go back. And you still can learn things from it. I think, I think we can sometimes understand, from an intellectual perspective, like, yes, I get that you need to fail. You need to do this to do that. But then when people get into it can be really, it can be hurtful in a way that isn’t just to the timing that they’re in, but there are so many other things that they haven’t worked through or processed through that it feels like they’re just stacking it on. Like, and now this, and now that, and my God, and now my shoes, and now this. It’s like, you’re just adding things to it. But it can be really easy to do that when you’re in that dark spot. Now, obviously you’ve been through these different things. You’ve fucked around, found out, but you’ve also learned through all this stuff. And I joke with the like, well, here was this short little thing. Like how they even do it in movies. Like all this chaos and craziness happened and like 15 minutes later, it’s like, no, there was a lot of dark times, but there’s still that momentum and that movement. Even if you’re slowing down and you’re resting, you’re still moving in that direction. So the fact that you just didn’t give up, like, let’s be real, man, you had a lot of different times you could have just totally checked out. You could have been like, no, this is too much. I’m not doing it. And now, like, have you thought about that? Like, what have you checked out? You wouldn’t be where you’re at. You wouldn’t be doing what you’re doing. You know, maybe you’re selling insurance again and like, fuck this, I can’t. Damon Cart (33:47.039)And I, you know, when I had that major failure, that’s what I thought. I was like, okay, do I have to go back into insurance? And I was seriously considering that. And, man, it was so painful to just even think about that. what I see with a lot of people, the real difference between people who are living the life that they want to live and really fulfilled by that and experiencing the kind of freedom they want is… They stuck with what they were doing, even if that like evolved, you know, because you try things, they fail, you keep trying new things. And so it evolves, but you’re still sticking with it. And what I would say is, you know, the really important thing is not to be so fixated on how you’re going to get there because I, if I had actually gotten what I wanted the way that I thought I wanted it, it would have been a lot more restrictive. I would have been having to show up, you know, just to keep my money going out, to actually physically show up in many different places and be teaching constantly, which is, you know, that’s what my teachers were doing. So I thought, well, that’s how it’s done. But they hadn’t really tapped into the Internet and YouTube and all that. So now I get the choice if I want to do that. I don’t have to like do that all the time. So I learned enough about, you know, business and everything to make it work the way that I make it work now. But that only came because the way that I thought I was going to do it failed miserably. So had to try to had to find a new way. Nick McGowan (35:06.633)Hmm. Damon Cart (35:08.192)When I think about like, had this weird experience earlier this year, was, so my wife and I, also my wife’s Romanian and we have a home in Romania. So we always go there in January and then we went to Cambodia and then we went to Vietnam. And I remember just like it really hitting me how much I was driven by freedom. And this is another thing that I think is really important to understand is when you, when you focus on values, then you’re not so focused on how you think it has to happen. You become more flexible and you know what. the values are that you’re after. And for a long time, freedom was such an important thing to me. And I remember earlier this year being in Vietnam and just being like, more freedom is not going to make me happier. More freedom is not going to make me more fulfilled. I have really hit that level of freedom that was far more than I expected to ever achieve. I can travel anywhere and go anywhere because I can run my business off of a laptop. And also have a great team of people who I work with who, you know, I don’t have to do everything. Nick McGowan (35:50.761)you Damon Cart (36:07.598)They’re there for that as well. So I have the money I need and I have all the freedom to travel and do whatever. And that was both a victory in that moment that I realized that, but it was also like, okay, so where do I go from here? And it was like a real question for me to sort of contemplate. And that’s, I that might sound a little arrogant, like you achieve all that you want and then you’re kind of like, okay, well, what do I do now? Like that’s a… a first world problem that most people would want to have that don’t even get to that point to have. it’s be prepared for that. Like if you really believe you’re going to be successful and you’re not going to stop until you become successful, be prepared for those moments that you have where you go, wow, OK, I really have it now. What now? And so I thought about all these different things that I could do from that point on. And I was like, well, wait a minute. It’s not about doing something different. I’m so happy with what I’m doing now. I don’t need to do anything different. I just want to do more of what I’m already doing. Nick McGowan (37:05.094)Yeah. Damon Cart (37:05.26)and I don’t need more freedom to do that. And it was a realization of I don’t need to be pursuing freedom so hard anymore because more of it actually can, at this point in my life, would probably be more nihilistic or more escapism. And it’s like, that’s not worth that either because that’s not gonna fulfill me more. So it was an interesting realization to come to that. And it’s like, yeah, okay, freedom doesn’t have to be the main thing here anymore. Nick McGowan (37:22.481)Mm-hmm Nick McGowan (37:33.874)Well, I think we’re also taught in this world with all the systems we have that you have to have a destination. Like think about even being like in high school and they’re like, we, need a five or you need a 10 year plan. That was always so difficult. I remember somebody even years ago was like, well, what’s your five or 10 year plan from now? It’s like, fuck if I know, because anything I come up with is going to be like half-hearted and like what I kind of want right now. But as you’ve moved through things and you do things, you start to see, well, I really want this. I want that. Like freedom is a big thing. I think a lot of people want freedom. I. Damon Cart (37:43.822)Hmm. Hmm. Nick McGowan (38:03.706)I love the freedom that I have. I’m right there with you where it’s like one of those things where you go, well, cool, I have it. Well, that’s cool. But like what’s really fulfilling inside is the thing that actually just drives us and pulls us from basically our chest. So for the people that are on their path towards self mastery and with everything you’ve gone through and especially with NLP, what’s your advice for those folks? Damon Cart (38:26.318)Keep your attention on what’s most important and what’s most important is your values. A value is a generalization about an experience that is important to you. So if happiness is important to you, success is important to you, authenticity is important to you, always keep your eyes on that. And then any goals you set need to be aligned with those values. Most of the time people have no idea what their values are in a particular context and they will be different from context to context. And they just set a goal because they think, okay, like you said, You have to have a destination, right? So here I’m going to set this goal, but they don’t really understand what’s driving the motivation to have that goal. And a lot of times it’s more external values. Well, other people value achieving this, so it must be valuable. Or if I achieve it, then these people will think very highly of me and respect me. Those are, you know, if you’re accomplishing something that does those things, there’s nothing wrong with that. But if that’s why you’re doing it, you’re probably not going to be fulfilled. by accomplishing that. And so a lot of people are chasing goals that are not even fulfilling to them. And whenever they fail at that, because really there’s that inner wisdom that is holding them back, like the inner wisdom that helped me back from succeeding as an insurance agent, because that would have been the golden handcuffs. It would have been really hard to walk away from a very successful business with a lot of money. And I would have probably tolerated that misery. you want to be careful. know, like when you quit at something because you run out of motivation for it. Nick McGowan (39:45.318)Hmm. Damon Cart (39:52.345)Check in with that is that a deeper wisdom that knows better that that’s not really going to fulfill you. But what most people do is they beat themselves up and they say, I should have had more discipline or I should have had more willpower. I’m just not good enough. And they go into this whole self-worth thing, which is not real by the way. It’s something that holds a lot of people back. And then the people who do succeed at it and they get there and they go, wow, this isn’t fulfilling. This feels rather empty. thought it would be great if when I finally Nick McGowan (40:03.791)Yeah. Nick McGowan (40:08.454)the Damon Cart (40:21.39)Achieve this but again, it wasn’t aligned with their values. So no, it’s not going to be fulfilling and Because they feel lost without a goal They set another goal and get back on that treadmill and they do the whole thing over and over again and people come to me for coaching now who are very very successful on paper you would think they would be extremely happy and fulfilled they have all the money they have the family they have the cars the house and everything and they’re coming to me because they feel like imposters or they’re coming to me because they feel so unfulfilled and they can’t understand it because they’ve accomplished everything they’ve ever wanted to accomplish yet they feel so empty inside. And it’s like, yeah, you’re good at accomplishing. The problem was you never really got in touch with what do you truly value? What is really important to you? And so that’s the most important thing is what’s most important to you. And the better you understand that, the more clarity you have around that, the more you’re naturally going to be drawn to that and motivated to do that. The other thing I would say is There is no such thing as self-worth. How this problem comes up is feeling like you’re not good enough, feeling like you deserve it or don’t deserve it. It goes both ways. And so what most people are feeling is a low sense of self-worth. And they feel like if I go and try to achieve something and I fail at it, I will lower my self-worth and I’m already clinging to what little I have. So most of the time people won’t do something and they’ll sit back and say, well, I’m waiting for the right opportunity. what they’re waiting is to feel of higher self-worth so that they feel like they can go do something and if they lose some self-worth, they’ll still be okay. Well, here’s the thing, there is no such thing as self-worth. There is no way to measure your value, which is what worth is. It’s really a metaphor and there’s a lot of problems that happen when we try to apply metaphors literally. And we see this in the Bible. Fundamentalists are people who are trying to apply metaphors in the Bible literally and it causes a lot of problems. So what people do is they have this idea of self-worth. And so they think, well, how do I measure my worth? Well, first of all, there’s no way to do it. There’s no objective scale or person who can be objective and measure people’s worth. So what do we do? We compare ourselves to others and that will destroy you every time. If you compare yourself to others to make yourself feel better about yourself because you think they’re less than you. Now you’re engaging in the superiority that’s going to bring you down. And if you play that game, you can’t only play it in one direction. Damon Cart (42:45.87)when you encounter someone you think is of higher worth than you, now you’re gonna feel bad about yourself. The whole thing, you can kill the whole thing just by stop comparing yourself to others. Now this idea of self-worth, it usually comes about very early in life and we just pile more and more beliefs on top of that whole idea. So the two things that I would recommend is get clear and clear about your values, basically what’s important to you. What does that actually look like to you? And you’re not going have it all figured out. And you’re definitely not going to figure it out all out on paper. You need to take action. And action is the best way to get that clarity, experience. And then the other thing is to dismantle the whole concept of self-worth entirely. When you do that, when you do those two things together, you’re just on the path to living a very fulfilling life, a life of being who you want to be and therefore creating the life you want to live. Nick McGowan (43:38.213)That’s awesome. And I think a lot of people can anchor into like the understanding of action and motivation too. Like you have to take action to be motivated, continue to do the thing. It’s likewise with what you’re saying where you have to take those actions, but you have to understand why you’re doing those things. And it is interesting how a lot of people don’t know what their principles are or they are somebody else’s principles. Like, well, my wife and I, or my partner and I, or my family and I, have these principles. Like, well, where did those come from? Well, you know, they just kind of came up and like, we don’t really think about that or don’t think about it throughout their day to day life of like, well, how do I move about this? And why do I want to do such a thing? I’m really glad that you touched on those two things, man. It’s been great having you on. So I appreciate your time. Before I let you go, where can people find you and where can they connect with you? Damon Cart (44:27.852)Yeah, the easiest place is my YouTube channel. It’s just Damon Cart, Damon Cart NLP. And we’ve got a lot of videos been doing this for quite a while, almost 10 years. So that’s, you’ll find not only my videos, but in my videos, I give a lot of free resources so that you can get started usually on the topic that I’m giving you or the solution to a problem. You can access like free PDFs and things like that. so also I have my website is selfconcept.com. Like I said, I do general NLP, but I also really focus on this one model because your beliefs about yourself determine your beliefs about everything else, you the world around you. And if you haven’t realized already, it’s your beliefs that govern your reality. So what you believe is possible, what you believe is true. lot of, most of our beliefs are deeply unconscious. So when you can understand what the beliefs are, especially the deeply unconscious ones about who you are, when you understand what those are, you understand their limitations and then you transform them so they don’t have those limitations. Then you become that person you value. Your self-esteem goes up, your confidence goes up and you naturally gravitate toward creating that life that you want to live that’s reflective of the value that you are. Nick McGowan (45:45.38)So wait, you putting worth to that? No, I’m just kidding. I’m only kidding. Awesome, man. Well, again, I appreciate your time. Thank you so much for being with us today. Damon Cart (45:48.052)It’s different, worse than the measurement. Damon Cart (45:55.246)Thank you for having me on.

Networking não é sobre cartões de visita. É sobre criar pontos e manter o capital relacional em circulação. No palco do FROTA Summit 2025, Pedro Waengertner traz uma nova perspectiva sobre como cultivar conexões genuínas em tempos de excesso de tecnologia e escassez de atenção.Mesmo sendo introvertido, Pedro construiu sua trajetória com base em redes diversas e mostra, com histórias reais, como o valor das conexões está mais em como nos relacionamos do que em quantos contatos temos. Ele fala sobre o poder dos laços fracos, a importância de combinar mundos diferentes e a arte de ser útil antes de ser lembrado.Também discutimos:Por que a automação esvazia o valor das conexões digitaisComo pequenas ações criam grandes oportunidades no futuroE por que manter sua rede ativa é tão importante quanto atualizar o currículoSe você acha que networking é forçado, ou não sabe por onde começar, este episódio pode mudar sua forma de enxergar (e cultivar) relações profissionais.Dá o play e vem com a gente!

This month, the multitalented Tawny Platis joins the gals to tell stories of abstract art, an immersive job interview, Kim Crawford's betrayal, flying cornucopias, Mama Mia showdowns, a haunted footprint, and a woman who did not marry her brother. Tune in for December's episode of Gossip at the Corpse Cart! For more info on Tawny's many talents, go to https://tawnyvoice.com/ For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Audio roundup of selected biopharma industry content from Scrip over the business week ended December 12, 2025. This week, a focus on five key results from the American Society of Hematology (ASH) meeting – Jaypirca headed for the front line; Kite's Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia's early in vivo CAR-T data; and Novartis's ianalumab's potential in ITP. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RFOOY2665REEZEN5SMJ2GW27EY/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Dans ce dernier numéro de l'année du Journal des biotechs, André Choulika, PDG de Cellectis revient sur les résultats marquants d'éti‑cel dans le lymphome réfractaire et détaille la stratégie avec IL‑2. Il évoque également les avancées cliniques attendues sur UCART22 et 20/22 et donne les rendez-vous importants de l'année 2026. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Ein kurzer Blick auf die Profi-Welt: DP World Tour in Südafrika, ein Stechen, deutsche Ergebnisse und der Ausblick Richtung Mauritius. Dazu die Q-School-Realität bei den Herren – und deutlich freundlichere Nachrichten aus dem deutschen Damengolf: LPGA-Karten, starke Namen, viel Substanz. Dann wird's alltagstauglich – und streitbar: Slow Play. Warum wirken Zweier- oder Dreierflights hinten raus plötzlich zäh? Wieso verlieren Vierergruppen Zeit, ohne einen einzigen Schlag mehr zu machen? Die drei sprechen über Ready Golf, über überlange Routinen à la Patrick Cantlay, über Vorbereiten statt Rumstehen – und über den Klassiker: Bag, Trolley oder Cart bitte dahin, wo man nach dem letzten Putt wirklich weitergeht. Plus: Schlangen-„Taktiken“ beim Ballsuchen, deutsche Tempo-Klischees im Ausland und ein Indoor-Abend in Valderrama als (leicht chaotisches) Lehrstück. Highlights Tour-Update: Südafrika, deutsche Platzierungen und der Blick nach Mauritius Q-School-Checks: Korn Ferry statt PGA – und was das sportlich bedeutet Deutsches Damengolf: LPGA/LET als Lichtblick und warum das gerade funktioniert Slow Play zerlegt: Ready Golf, Routinen, Suchzeiten – wo Runden wirklich hängen Trolley- und Bag-Position: die unterschätzte Minuten-Frage am Grün Indoor-Golf als Winterformat: Spaßfaktor hoch, Ernsthaftigkeit runter

durée : 00:03:28 - Les P'tits Bateaux - par : Camille Crosnier - Aujourd'hui, Adèle se demande pourquoi toutes les personnes n'ont pas la faculté de faire des acrobaties comme par exemple le grand écart, la roue ou le poirier ? La danseuse étoile Dorothée Gilbert lui répond. - invités : Dorothée Gilbert - Dorothée Gilbert : Danseuse étoile dans le Ballet de l'Opéra de Paris - réalisé par : Stéphanie TEXIER Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Diálogos à luz do Evangelho e da Doutrina Espírita.Reflexões sobre o tema "NA CULTURA DA PAZ", com base NO CAP. 54 do livro: CEIFA DE LUZ, de Emmanuel, psicografia de Francisco Cândido Xavier. BIBLIOGRAFIA:- Livro: Ceifa de Luz - Emmanuel, psicografia de Francisco Cândido Xavier, cap. 54 – “Na Cultura da Paz” - disponível em: https://bibliadocaminho.com/ocaminho/TX/Cel/Cel54.htm- Livro: Novo Testamento - Mateus - capítulo 7 - versículo 12 - disponível em: https://bibliadocaminho.com/ocaminho/TRP/Mt/Mt07.htm#V7- Livro: O Evangelho Segundo o Espiritismo - Allan Kardec - Cap. 9 - Bem Aventurados os Que São Brandos e Pacíficos - disponível em: https://bibliadocaminho.com/ocaminho/TKP/Ev/Ev09.htm- Livro: Livro da Esperança - Emmanuel - Cap. 21 - Pacificação - Emmanuel - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Le/Le21.htm- Livro: Palavras de Vida Eterna - Emmanuel - Cap. 70 - Pacifica Sempre - Emmanuel - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Pve/Pve70.htm- Livro: Urgência - Emmanuel - Cap. 4 - Ação e Paz - Emmanuel - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Ur/Ur04.htm - Livro: Filho de Deus - Joanna de Angelis - Cap. 2 - Paz em Ti - Joanna deAngelis - psicografia de Divaldo P. Franco - disponível em: https://semeandoestrelassite.wordpress.com/wp-content/uploads/2017/09/filho-de-deus.pdf- Livro: Crônicas de Além Túmulo - Humberto de Campos - Cap. 24 - A Paz e a Verdade - Humberto de Campos - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Cat/Cat24.htm- Livro: Material de Construção - Emmanuel - Cap. 36 - Aula de Paz - Emmanuel - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Mac/Mac36.htm- Livro: Busca e Acharás - Emmanuel/André Luiz - Cap. 8 - Cartões de Paz - André Luiz - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Ba/Ba08.htm- Livro: Nós - Emmanuel - Cap. 3 - Conquista da Paz - Emmanuel - psicografia de Francisco C. Xavier - disponível em: https://bibliadocaminho.com/ocaminho/TX/Ns/Ns03.htm

The Golf Competence Achievement & Reward Test, otherwise known as the golf CART™, can help you put your year in perspective. Sam Weinman and Golf Digest social guru Will Irwin walk us through the process and share their scores. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this Review Series episode, Blood Associate Editor, Dr. Elisabeth Battinelli discusses the Platelet Heterogeneity with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai.  Find the full review series in volume 146 issue 24 of Blood. 

As many of you have probably heard, two giants in Hollywood are now competing to merge with one another. Netflix is attempting to acquire Warner Bros., while Paramount has also submitted its own bid for the company. But what does this actually mean, especially for filmmakers? Nino and Johnnie break it down in detail in this episode, along with a range of other compelling topics.   Chapters and Articles in This Episode (00:00) - Intro (01:02) - Netflix Acquires Warner Bros. Discovery for $83 Billion – Streaming Giant's Business Model Poses Existential Threat to Theatrical Exhibition https://www.cined.com/netflix-acquires-warner-bros-discovery-for-83-billion-streaming-giants-business-model-poses-existential-threat-to-theatrical-exhibition/ (24:26) - Death of the Triple-Camera Phone? Sony LYTIA 901 Sensor Does 4x Zoom Without Extra Lenses https://www.cined.com/death-of-the-triple-camera-phone-sony-lytia-901-sensor-does-4x-zoom-without-extra-lenses/ (36:20) - Mavis Camera Introduces Film Kit – LUT Workflows, Open Gate Capture, and Apple Log 2 Support https://www.cined.com/mavis-camera-introduces-film-kit-lut-workflows-open-gate-capture-and-apple-log-2-support/ (39:40) - DIGILOG Camera iPhone App Brings Kodak 500T Film-Inspired Look, Open-Gate ProRes Recording, Free Download https://www.cined.com/digilog-camera-iphone-app-brings-kodak-500t-film-inspired-look-open-gate-prores-recording-free-download/ (42:27) - Tilta Nucleus Auto Focus Adapter Explained – Unlock the Full Potential of Every Manual Lens https://www.cined.com/tilta-nucleus-auto-focus-adapter-explained-unlock-the-full-potential-of-every-manual-lens/ (51:02) - Middle Control 3 Pro Brings Sony Camera Control to Blackmagic ATEM Switchers https://www.cined.com/middle-control-3-pro-brings-sony-camera-control-to-blackmagic-atem-switchers/ (56:45) - The Story Behind the Ken Burns Effect: How a Phone Call From Steve Jobs Made Documentary's Most Influential Technique a Household Name https://www.cined.com/the-story-behind-the-ken-burns-effect-how-a-phone-call-from-steve-jobs-made-documentarys-most-influential-technique-a-household-name/ (01:02:44) - Audiio Voices Introduced – Record Your Voiceover and Transform It into a Professional Style https://www.cined.com/audiio-voices-introduced-record-your-voiceover-and-transform-it-into-a-professional-style/ (01:06:17) - Imagen AI Introduces Adaptable AI Color Grading, Free Beta Access, and More https://www.cined.com/imagen-ai-introduces-adaptable-ai-color-grading-free-beta-access-and-more/ (01:09:12) - fylm.ai Update – Adds Adobe Premiere Extension for Seamless Collaboration and Full Remote Grading https://www.cined.com/fylm-ai-update-adds-adobe-premiere-extension-for-seamless-collaboration-and-full-remote-grading/ (01:12:42) - Apple Vision Pro Strategy For Immersive Video Production: Live Sports, Static Foveation, And Monetization Challenges https://www.cined.com/apple-vision-pro-strategy-for-immersive-video-production-live-sports-static-foveation-and-monetization-challenges/ (01:17:00) - Cartoni Ragno Pod Announced – Portable Tripod Riser with 100kg Payload, 629mm Elevation https://www.cined.com/cartoni-ragno-pod-announced-portable-tripod-riser-with-100kg-payload-629mm-elevation/ (01:20:04) - ZILR ZIPR Introduced – An E-Powered K.I.T. Cart for Production Mobility https://www.cined.com/zilr-zipr-introduced-an-e-powered-k-i-t-cart-for-production-mobility/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Why did a DoorDash driver allegedly douse a food order in pepper spray, causing a customer to choke? Lionel unpacks the terrifying realities of modern delivery culture, from Amazon buggies to apartments acting as UPS stores. Then, it's a deep dive into culture and controversy: discussing the resurgence of traditional Latin Mass among young people and debating concepts of tradition, assimilation, and identity in America. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of transformative events shaping the future of drug development, patient care, and global healthcare strategies.**Johnson & Johnson's Multiple Myeloma Advances** Johnson & Johnson has made significant strides in the treatment of multiple myeloma with their bispecific antibody, Tecvayli. In recent trials, Tecvayli has shown remarkable promise when used in combination therapies as a second-line treatment. This development is noteworthy as it could potentially challenge the dominance of CAR-T cell therapies like J&J's Carvykti by offering a more accessible and less complex alternative. For patients, this means potentially fewer logistical hurdles and a more straightforward therapeutic option, which could drastically improve patient care standards.**Regulatory Scrutiny on RSV Vaccines** Turning to regulatory news, the U.S. FDA has intensified its scrutiny of respiratory syncytial virus (RSV) vaccines developed by pharmaceutical giants such as Merck, AstraZeneca, and Sanofi for infants. This increased oversight follows reports linking some COVID-19 vaccines to adverse effects in children. The FDA's actions highlight the ongoing necessity for vigilant safety monitoring in vaccine development, especially for vulnerable populations like infants. This is a crucial step in ensuring that vaccines designed for our youngest population are both safe and effective.**Eli Lilly's Strategic Moves in Oncology and Beyond** Eli Lilly is making waves in oncology with its BTK inhibitor, Jaypirca. Despite strong phase 3 results that support its use as a first-line treatment for chronic lymphocytic leukemia (CLL), Lilly is focusing on its application as a second-line therapy. This strategic choice reflects an astute understanding of market dynamics and therapeutic niches where Jaypirca can provide substantial benefits despite competition from established first-line treatments. Additionally, Eli Lilly continues to leverage its financial success from its weight loss drug Tirzepatide to position itself as a central player in global pharmaceutical innovation. The company's strategic investments are likely to catalyze advancements across various therapeutic areas, reinforcing its role as a key contributor to medical breakthroughs.**Legislative Impact on Biopharma** In legislative news, the Biosecure Act's incorporation into the U.S. National Defense Authorization Act marks a strategic shift towards tightening regulations on Chinese biopharma entities regarding federal contracts by 2026. This move could have profound implications for international collaborations and competition within biotechnology innovation and drug development sectors. It signals a broader trend of increased scrutiny on foreign entities in sensitive industries like biopharmaceuticals.**China's Healthcare Transformation** China's healthcare landscape is undergoing significant transformation with the inclusion of drugs from companies like Pfizer, Lilly, and J&J into its first private insurance formulary. This development could enhance access to innovative medications within China, potentially improving health outcomes and influencing global pricing strategies in the pharmaceutical industry.**Gamida Cell's Milestone in Cell Therapies** In a major milestone for cell therapies, Gamida Cell has secured a second FDA approval for its stem cell therapy Omisirge. Initially approved to reduce infection risk during hematopoietic stem cell transplantations in blood cancer patients, Omisirge's expanded indication to treat severe aplastic anemia underscores the potential of cell therapies in addressing diverse hematologic conditions.**CSL Seqirus' New Facility in Australia** In Australia, CSL Seqirus has opened a $1 billion facility dedicated to producing cell-baSupport the show

>>Take the 450th podcast episode player survey to enter into tons of awesome gifts! >>Read the holiday gift guides:  Best Golf Gifts in 2025  Best Golf Gifts for Men  Best Golf Gifts for Women  Luxury Golf Gifts  Best Golf Gifts for Kids  Best Golf Gifts Under $100 Today I'm sharing an episode where I was a guest on 2 Dudes, 1 Cart podcast. In this episode, we'll cover: Why you need a highlight reel How to overcome slumps faster than ever How the 8-second secret can transform your scores  The art of playing better under pressure and tournaments  And more strategies to play consistent golf using wicked smart strategies.  WICKED SMART GOLF Recommended Products Think Like a Pro with DECADE Golf: The #1 course management system to think like a pro (use code WICKEDSMART to save 20%). Speed Train With Rypstick: The #1 speed trainer to add 10+ yards in 40 days or less (use code WICKEDSMART to save 20%)  Master Mobility & Flexibility with Golf Forever: The best way to work on your golf fitness at home or the gym, with easy to follow plans & app (use code "WICKEDSMART" to save 15%).  Use HackMotion for Better Ballstriking: The best wrist trainer in golf and become your swing coach (use code WICKEDSMART to save 5% on your investment).  Wicked Smart Golf Academy To Lower Your HDCP Fast: The FASTEST way to play consistent golf.  Practice Like a Pro With Wicked Smart Golf Practice Formula: 75+ Practice plans and a 90-minute masterclass to practice like a pro.   Also, don't forget to connect on social media: Follow on TikTok Follow on Instagram   Subscribe on YouTube Read or listen to Wicked Smart Golf on Amazon or Audible (ideal for beginner to intermediate golfers who want 111 ways to play better without swing changes.  Read or listen to Wicked Smart Golf II on Amazon or Audible (perfect for golfers looking to break 80 consistently).  Read or listen to Wicked Smart Golf III on Amazon or Audible (best for players wanting to dominate competitive events).

CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center's community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy.     "Education of community oncology staff at their offices—coordinators, nurses, physicians, advanced practice providers—also goes a long way in helping facilitate patients to be recognized when they are candidates for cell therapy." - Jeremy M. Pantin, MD, FACP "It did not matter the distance to the center; did not matter the socioeconomic background. Many of the other factors one would think would lead to decreased access, we did not find among our centers. It was really the delay from consult to treatment." - Jeremy M. Pantin, MD, FACP    Guest:                  Jeremy M. Pantin, MD, FACP Clinical Director, Adult Transplant and Cellular Therapy Program Sarah Cannon Transplant and Cellular Therapy Network At TriStar Centennial Medical Center Nashville, TN   Resources: Bringing CAR T-Cell Therapies to Community Oncology   Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring   FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies

Radio Foot, deux émissions en direct ce mardi à 16h10 T.U. et 21h10 T.U. : - Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. ; - Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. ; - À suivre également : FC Barcelone/Francfort. Bergame/Chelsea. Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. Des Nerazzurri toujours candidats au titre, qui marquent beaucoup et feront face à des Reds en crise, qui encaissent beaucoup, et traversent une tempête médiatique provoquée par Mo Salah. L'Égyptien ne sera pas du voyage. Les Scousers n'ont remporté que 4 de leurs 15 derniers matches toutes compétitions confondues, comptent 3 succès pour 2 défaites dans la compétition. - Bayern/Sporting, les Bavarois pratiquement assurés de poursuivre l'aventure mais doivent renouer avec la victoire après le faux pas d'Arsenal. Les Lisboètes pointent à la 8è place et espèrent une qualification directe pour les 8ès de finale.   Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. Ils auront fort à faire face à Jakobs, Gündogan, Sané et Osimhen. Retour de Pogba en Ligue des Champions, du temps de jeu pour le milieu international ? - Réagir après la défaite de Lille. C'est l'objectif de l'OM, mais attention à l'Union Saint Gilloise, champion de Belgique. Une équipe joueuse et compétitive, mais qui n'évoluera pas dans son stade.   À suivre également : FC Barcelone/Francfort. Leaders de Liga, les Catalans doivent se reprendre après la déconvenue de Chelsea. Avec un point en quatre rencontres, les Aigles doivent faire un résultat au Camp Nou. - Bergame/Chelsea, match crucial pour les 2 équipes. Une Dea irrégulière face à des Blues privés de Cole Palmer, qui veulent figurer dans le top 8. Avec Olivier Pron : Nicolas Vilas, Nabil Djellit, Bruno Constant et Thomas de Saint-Léger à Monaco. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go in the year. On the latest BioCentury This Week, BioCentury's analysts discuss the rise in large M&A deals and what the trends among the 37 acquisitions say about biopharma dealmaking.The analysts assess first-in-human in vivo CAR T data at the American Society of Hematology meeting from Kelonia Therapeutics, which showcase the promise of the modality and justify the growing pipeline. They also break down readouts from Praxis in developmental and epileptic encephalopathy from the American Epilepsy Society Annual Meeting and from Novo Nordisk, which presented full data at the Clinical Trials on Alzheimer's Disease meeting on semaglutide's failure to treat Alzheimer's disease.Washington Editor Steve Usdin analyzes a roller-coaster week at FDA in which Richard Pazdur resigned as director of FDA's Center for Drug Evaluation and Research and Tracy Beth Høeg became acting CDER director, a move that Usdin says will prompt staff departures, ease restraints on FDA leadersView full story: https://www.biocentury.com/article/657781#BiotechMA #CARTTherapy #EpilepsyResearch #AlzheimersDisease #FDA02:37 - Biotech M&A06:39 - In vivo CAR T10:08 - Semaglutide for Alzheimer's16:17 - Praxis22:11 - FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Radio Foot, deux émissions en direct ce mardi à 16h10 T.U. et 21h10 T.U. : - Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. ; - Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. ; - À suivre également : FC Barcelone/Francfort. Bergame/Chelsea. Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. Des Nerazzurri toujours candidats au titre, qui marquent beaucoup et feront face à des Reds en crise, qui encaissent beaucoup, et traversent une tempête médiatique provoquée par Mo Salah. L'Égyptien ne sera pas du voyage. Les Scousers n'ont remporté que 4 de leurs 15 derniers matches toutes compétitions confondues, comptent 3 succès pour 2 défaites dans la compétition. - Bayern/Sporting, les Bavarois pratiquement assurés de poursuivre l'aventure mais doivent renouer avec la victoire après le faux pas d'Arsenal. Les Lisboètes pointent à la 8è place et espèrent une qualification directe pour les 8ès de finale.   Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. Ils auront fort à faire face à Jakobs, Gündogan, Sané et Osimhen. Retour de Pogba en Ligue des Champions, du temps de jeu pour le milieu international ? - Réagir après la défaite de Lille. C'est l'objectif de l'OM, mais attention à l'Union Saint Gilloise, champion de Belgique. Une équipe joueuse et compétitive, mais qui n'évoluera pas dans son stade.   À suivre également : FC Barcelone/Francfort. Leaders de Liga, les Catalans doivent se reprendre après la déconvenue de Chelsea. Avec un point en quatre rencontres, les Aigles doivent faire un résultat au Camp Nou. - Bergame/Chelsea, match crucial pour les 2 équipes. Une Dea irrégulière face à des Blues privés de Cole Palmer, qui veulent figurer dans le top 8. Avec Olivier Pron : Nicolas Vilas, Nabil Djellit, Bruno Constant et Thomas de Saint-Léger à Monaco. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Pressure doesn't look dangerous—until the instant it is. We take you right to the two moments that matter most in filter service—when the lid comes off and when it goes back on—and show you how to turn a risky task into a safe, repeatable routine.We start by reframing the filter as a pressure vessel, not a harmless canister. Sand filters are usually one-piece and lower risk; cartridge and DE filters come apart, rely on clamps or locking rings, and can fail if misaligned or under-tightened. You'll hear why modern safety designs like the Aquastar Pipeline's interlock are so effective and how to apply the same logic on any system: power down, bleed air, drain, and verify zero pressure before loosening hardware.From there, we share practical safeguards that work in the field. Put automation in service mode, move Intermatic trippers, or cut the subpanel, but don't stop there—remove the pump lid so the system can't prime even if a glitch starts the motor. We talk through clamps in detail: reading spring-barrel nuts, preventing cross-threading with a touch of lube, knowing when a clamp is cosmetic-ugly yet structurally sound, and when to replace hardware for peace of mind. On restart, we step back, open the air relief, and wait for water before approaching. A spiking gauge is your red flag for a blocked return or a clogged salt cell; shut down fast, clear the path, and protect the tank.• treating the filter as a pressure hazard• relative risks of sand, cartridge, and DE filters• turning off power and automation service mode• removing the pump lid as a fail-safe• bleeding air and safe startup distance• clamp types, tightening until spring coils meet• avoiding cross-threading and when to replace clamps• spotting dangerous pressure spikes and return blockages• quick priming tips and avoiding automation glitches• training techs to follow a standard safety checklistLearn more at swimmingpoollearning.com  On the banner, there's a podcast icon—click for the archive  Learn more at PoolGuyCoachinSend us a textSupport the Pool Guy Podcast Show Sponsors! HASA https://bit.ly/HASAThe Bottom Feeder. Save $100 with Code: DVB100https://store.thebottomfeeder.com/Try Skimmer FREE for 30 days:https://getskimmer.com/poolguy Get UPA Liability Insurance $64 a month! https://forms.gle/F9YoTWNQ8WnvT4QBAPool Guy Coaching: https://bit.ly/40wFE6y

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of pivotal events shaping the landscape of drug development and patient care. The interplay between scientific advancements, regulatory shifts, and strategic partnerships is setting the stage for significant transformations within the industry.A highlight of recent developments is the legal challenge faced by Merck & Co. regarding its new subcutaneous version of Keytruda. This immunotherapy, already a breakthrough in cancer treatment, has encountered a hurdle in Germany where Halozyme, known for its drug-delivery technologies, has secured a preliminary injunction. This move by a German court halts Merck's activities related to Keytruda SC in Germany and underscores the intricate web of intellectual property rights in drug launches across international markets. The outcome of this case could establish crucial precedents for future commercialization efforts involving advanced drug delivery technologies.Meanwhile, there's promising news from Bristol Myers Squibb as their CAR-T therapy, Breyanzi, receives its fifth FDA approval, this time for marginal zone lymphoma. This approval is particularly noteworthy as it marks Breyanzi as the first CAR-T treatment sanctioned for this specific indication and extends its use across five different types of blood cancers. CAR-T therapies continue to represent a frontier in cancer treatment by leveraging the body's immune system to combat malignancies more effectively. This success story from Bristol Myers Squibb highlights the expanding potential of CAR-T therapies in tackling various hematological cancers, offering renewed hope for patients with limited treatment avenues.On the regulatory front, the FDA's proposal to consider single-trial approvals for certain drugs has sparked considerable debate. While some industry voices express concerns about potential compromises to safety and efficacy standards, others see it as an opportunity to invigorate research and development investments by reducing both time and costs associated with bringing new therapies to market. This shift could indeed accelerate innovation but will necessitate a careful balance to uphold rigorous safety standards.In parallel regulatory news, Daiichi Sankyo has received an "untitled letter" from the FDA over its patient ambassador video for Turalio, indicating ongoing challenges in navigating drug promotion guidelines and patient engagement strategies. Such interactions emphasize the complexities pharmaceutical companies face within regulatory frameworks.Shifting focus to corporate strategies, Mark Cuban's Cost Plus Drugs is exploring a partnership with Humana aimed at addressing prescription drug costs for employers. This collaboration seeks to reduce healthcare expenses through innovative pricing models and distribution channels, reflecting a broader industry trend toward cost containment and value-based care delivery.In another development affecting public health policy, the CDC's Advisory Committee on Immunization Practices has postponed its vote on changes to newborn hepatitis B vaccine policies due to ongoing debates and confusion surrounding the topic. This delay highlights the intricate nature of updating long-standing public health policies, especially those impacting vaccination schedules.From an investment perspective, Freenome's decision to go public through a $330 million SPAC deal stands out. Specializing in developing blood tests for early cancer detection using machine learning technologies, Freenome's move aims to secure capital necessary for advancing its diagnostic tools—potentially transforming cancer screening practices by enabling earlier detection and intervention.In clinical trial news, Praxis Precision Medicines reported positive efficacy results from a Phase 2 trialSupport the show

REDIFF - Lola se sent mise à l'écart et en manque de chaleur dans sa relation avec son plus jeune fils, récemment marié. Elle éprouve des difficultés à s'adapter à la nouvelle dynamique familiale, notamment en raison de différences sociales et culturelles avec la belle-famille. Elle cherche à comprendre comment maintenir une relation chaleureuse avec son fils tout en gérant ses propres sentiments de solitude et d'insécurité. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.fr.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Taken as a group, blood cancers are the fifth most common type of cancer in New Zealand - affecting around one in twenty people during their lifetime. But some patients are forced to seek help overseas because a treatment that could save them isn't available here. The Wellington based Malaghan Institute of Medical Research is working to change that. Winner of this year's Breakthrough Project category in the KiwiNet Awards, Malaghan is currently conducting phase two of its CAR-T cell therapy clinical trials. The therapy essentially uses the body's own immune system to target and kill cancer cells. Professor Robert Weinkove is the Clinical Director and he speaks to Mihi about the next major step in their push to make it a standard part of cancer care in New Zealand.

What happens when a dentist who started with pegboards faces down stage four cancer and emerges with the wisdom of 44 years in practice?In this deeply moving episode, Dr. Allison House and Shawn Zajas sit down with Dr. Michael Thompson, a pioneering Arizona dentist whose career spans from the pre-internet era to today's AI-driven landscape. This isn't just another career retrospective—it's a masterclass in building authentic dental practice while maintaining unwavering integrity.Dr. Thompson opens up about the pivotal moments that shaped his authentic leadership journey: from that first meeting with Dr. House at Bucky's Barbecue 25 years ago, to the gut-wrenching decision to replace 50+ failed crowns at his own expense, to facing his mortality with stage four lymphoma and choosing to dedicate his "bonus years" to mentoring the next generation at A.T. Still University.The conversation tackles the profession's greatest challenges with refreshing honesty. When did the pressure to produce 100 new patients a month become the industry standard? How do you maintain ethical practice when overhead keeps climbing? What's the real cost of losing human connection in an increasingly automated healthcare system?Dr. Thompson shares his three-part formula for daily success—feeling well-compensated spiritually, professionally, and financially—and why compromising any one dimension leads to burnout. He reveals how his father's dinner table lessons about entrepreneurship shaped his practice philosophy, why he believes "you're only as ethical as you can afford to be," and what it really takes to build 30-year patient relationships in an era of corporate consolidation.But perhaps most powerful is his cancer journey: diagnosed at 67 while in the prime of his practice, facing refractory stage four B-cell lymphoma, and ultimately experiencing what he calls "a story too good to be true" through CAR-T immunotherapy. His reflection on looking back without regrets—"I don't regret the things I did, I regret the things I didn't do"—offers profound wisdom for practitioners at every career stage.This episode is essential listening for any dental professional wrestling with authentic practice in today's commoditized healthcare landscape, seeking to understand how to maintain integrity when business pressures mount, or simply wanting to hear what sustainable success looks like over a four-decade career.Subscribe to the podcast on APPLE: https://podcasts.apple.com/us/podcast/the-authentic-dentist/id1487586274Or SPOTIFY: https://open.spotify.com/show/6qapfaNRkcIlCjgIsftb60?si=d02c74cf4f924897

In this special episode, Blood editor Dr. Laura Michaelis interviews Dr. Arielle Langer and Blood Associate editor Dr. Marc Blondon for this special Maternal Health episode. In honor of the second Maternal Health compendium, both discuss their papers featured in this special collection. Featured Articles: β-Thalassemia minor is associated with high rates of worsening anemia in pregnancyLongitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptivesSee the entire Maternal Health Compendium Second Edition

Aaron & Tom review the state of the holiday retail climate, the history of America's vapor economics, the CNN x Kalshi collab, and financing Air Jordans at 22% interest. Subscribe to our patreon today: https://www.patreon.com/trillbillyworkersparty

Live from the Amazon Warehouse in Robbinsville, in this episode of The Speed of Culture podcast, Matt Britton speaks with Amanda Doerr, Vice President of Core Shopping at Amazon, for a deep and practical look at how Amazon AI shopping is reshaping the entire buying journey. From the launch of Rufus AI shopping assistant and breakthroughs in AI review summarization to the rise of conversational commerce, voice commerce, and mobile-first e-commerce, Amanda shares how Amazon is solving customer friction and building the foundation for the future of e-commerce 2026.Follow Suzy on Twitter: @AskSuzyBizFollow Amanda Doerr on LinkedInSubscribe to The Speed of Culture on your favorite podcast platform.And if you have a question or suggestions for the show, send us an email at suzy@suzy.com Hosted on Acast. See acast.com/privacy for more information.

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS.  In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a chimeric antigen receptor, or CAR. Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment.  This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct4 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

Drs. Danilov and Coombs review the evolving treatment strategies for CLL, focusing on the use of CAR T-cell therapy and allogeneic stem cell transplant in different disease stages, particularly for patients with relapsed or refractory disease. They emphasize the importance of tailoring treatment to individual patient needs, considering clinical trials, and recognizing challenges.

Featuring a slide presentation and related discussion from Dr Matthew Lunning, including the following topics: Overview of available chimeric antigen receptor (CAR) T-cell therapies (0:00) Toxicities associated with CAR T-cell therapy (4:03) Mitigation strategies for adverse events (22:02) Novel strategies for outpatient infusion (26:34) Changes to the CAR T-cell therapy safety regulations (30:23) CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics: Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00) Overview of the CAR T-cell therapy administration process (4:40) Opportunities for referral for CAR T-cell therapy (10:05) Selection of a CAR T-cell therapy based on patient characteristics (16:09) Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23) Safety regulations and mitigation strategies for adverse events (30:36) Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16) Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09) Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09) CME information and select publications

Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here.

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

 In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where findings suggested that R-CHOP21 rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone, administered every 21 days) may be a suboptimal frontline regimen for PMBCL. Dr. Pinho discusses the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging.Featured Articles: Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging 

Send us a textWe are so excited to have Dr. Yasmin Mohseni back to to talk about the latest advances in the world of immunology! We discuss the recent Nobel Prize awarded for research on regulatory T cells (Tregs) and how they help keep inflammation and autoimmunity in check. We talk about the complexities of autoimmune diseases, particularly Inflammatory Bowel Disease (IBD), and why Tregs play such a big role in keeping the immune system balanced. Dr. Mohseni walks us through some of the most innovative treatments on the horizon, from cell therapies to CAR T-cell approaches, and even how AI might shape the future of medicine. We wrap things up on a hopeful note, looking ahead at where autoimmune treatments are going and why ongoing research matters more than ever.Dr.  Yasmin Mohseni, PhD is an immunologist with 6+ years of experience in the cell and gene therapy biotech space, specializing in immunotherapy for cancer and immunoregulation. Dr Mohseni earned her PhD in Immunotherapy from King's College London, where she focused on using engineered regulatory T cells (Tregs) to promote immune tolerance in solid organ transplantation with applications to autoimmunity. She began her industry journey at Quell Therapeutics, advancing Treg-based therapies, and now works at A2 Biotherapeutics in the cancer immunotherapy space, developing therapies for solid tumors. Find Dr Yas here: https://www.instagram.com/doctor.yas_/Takeaways-- Tregs are crucial for suppressing inflammation in the immune system.- The Nobel Prize recognition highlights the importance of Tregs in immunology.- Autoimmunity involves a complex interplay of genetic and environmental factors.- Tregs can be dysfunctional in autoimmune diseases, leading to chronic inflammation.- Cell therapy, including CAR T-cells, shows promise for treating autoimmune diseases.- AI is revolutionizing target discovery in immunology and personalized medicine.- The future of autoimmune treatments is hopeful, with ongoing research and innovation.- Understanding the mechanisms of Tregs can lead to better therapeutic strategies.- The balance of immune responses is critical in managing autoimmune diseases.Chapters-00:00- Introduction and Personal Updates03:40- Nobel Prize in Immunology: Tregs and Their Significance10:34- Understanding Autoimmunity and Inflammatory Bowel Disease (IBD)16:12- The Role of Tregs in Autoimmunity21:49- Exploring Cell Therapy and CAR T-Cell Approaches27:26- Future of Autoimmunity Treatments and AI in Medicine46:36- Conclusion and Future PerspectivesFollow us on instagram @crohns_and_colitis_dietitiansFollow us on youtube @thecrohnscolitisdietitiansWe love helping provide quality content on IBD nutrition and making it more accessible to all through our podcast, instagram and youtube channel. Creating the resources we provide comes at a significant cost to us. We dream of a day where we can provide even more free education, guidance and support to those with IBD like us. We need your support to do this. You can help us by liking episodes, sharing them on your social media, subscribing to you tube and telling others about us (your doctors, friends, family, forums/reddit etc). Can you do this for us? In return, I promise to continually level up what we do here.

The local non profit has been changing lives for decades now and they have a great idea for holiday gift giving, cookies! Find out more about this great organization from Jacquelyn Carpenter, the Executive Director of Cookie Cart.

Drew Ann Long's journey also underscores the complex realities faced by female entrepreneurs and mothers as they navigate the challenging waters of corporate America, especially within traditionally male-dominated spheres. Confronted by skepticism and bias, Drew Ann relied on a blend of strategic preparation and personal conviction, ensuring her rights and her invention's mission remained protected at every step. Her resilience and ability to balance the demands of business leadership and caregiving highlight the multifaceted nature of her success, demonstrating that enduring perseverance and emotional intelligence are as critical as any business skill. Her work with Caroline's Cart marks more than business accomplishment—it represents a larger cultural transformation toward recognizing and valuing the differently-abled community and their families. Through persistent advocacy and an unwavering mission for inclusion, Drew Ann has compelled major retailers to address a demographic previously overlooked in both product development and customer service. Additionally, with the founding of Caroline's Cause, she extends her impact even further, supporting not just those with special needs but the siblings whose contributions are often quietly heroic. Motivated by her remarkable story and commitment, Drew Ann Long encourages you to be part of the movement for greater accessibility, inclusion, and resilience. To learn more about her journey, speaking engagements, and ongoing advocacy, visit her website here. For the accessible version of the podcast, go to our Ziotag gallery.We're happy you're here! Like the pod?Support the podcast and receive discounts from our sponsors: https://yourbrandamplified.codeadx.me/Leave a rating and review on your favorite platformFollow @yourbrandamplified on the socialsTalk to my digital avatar Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Danilov and Coombs explore the potential benefits and challenges of CAR T-cell therapy in CLL, emphasizing the importance of personalized treatment decisions and shared decision-making between physicians and patients.

Ashlee finds out some information she wishes she never knew about her dadSee omnystudio.com/listener for privacy information.

Many see Amazon as a reliable source of consumer goods from toilet paper to wireless headphones. But Sean McLain reports that the “everything store” is now betting that consumers will also pick up much bigger items when given the opportunity. Plus, Imani Moise reports on why fintech company Block is sharing its version of a credit store with customers. Patrick Coffee hosts. Sign up for the WSJ's free Technology newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's Tarp Find mini-episode is a heartwarming story about Penn State football player Vega Ioane pitching in to lend a helping hand off the field. Programming Note: Nothing is changing with Andrew's weekly interview episodes. Andrew's interview episodes will continue to be in your podcast feed every Thursday morning again once Season 14 launches on January 8th.

Guest: Dr. Anderson is currently the Albert H. Coons Professor of Neurology at Harvard Medical School, Senior Scientist at the Brigham and Women's Hospital, Institute Member of the Broad Institute of MIT and Harvard, and Core Faculty Member of the Gene Lay Institute of Immunology and Inflammation. She talks about her research on immune regulation in cancer and enhancing anti-tumor immunity. (38:33) Featured Products and Resources: Submit your abstract now for IMMUNOLOGY2026! Download a free wallchart on the production of CAR T cells. The Immunology Round Up CAR Tregs for Atherosclerosis: Anti-oxidized low-density lipoprotein CAR Tregs reduce atherosclerotic plaque formation in mouse models. (2:20) Tumor-Reactive T Cells: Tumor-reactive CD8+ T cells can be isolated and expanded from clinical samples. (14:24) Harnessing Myeloid and Lymphoid Synergy for Immunotherapy: Myeloid-targeted immunocytokines and natural killer/T cell enhancers show potential for treating solid cancers. (18:50) Subcutaneous Fat Affects Intestinal Aging: Subcutaneous white adipose tissue dysfunction triggers aging-like intestinal dysfunctions in mouse models. (32:40) Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

God is asking you to follow him in a way that will require your faith. You're not going to understand it. You're not going to be in control of it. Can your mind make peace with the unknown? Can your hands remain open in full surrender? And girl, will your feet move forward to destination […]

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

durée : 00:15:29 - Journal de 8 h - Une petite musique revient, alors que le marathon budgétaire entre dans une semaine cruciale : et si le gouvernement utilisait finalement l'article 49.3 pour faire passer les deux projets de loi de finances ?

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

As part of our Hidden Killers 2025 Year in Review series, we revisit one of the most jaw-dropping chapters in the ongoing Bryan Kohberger case — the digital trail that may have done what he allegedly couldn't avoid in person: exposing him completely. Investigators say Kohberger, the Ph.D. criminology student accused of killing four University of Idaho students in November 2022, may have left behind more than DNA on a knife sheath — he may have left a shopping list. A damning set of online purchases allegedly includes a K-Bar knife, matching sheath, and sharpening tool — all conveniently ordered from Amazon. In this Hidden Killers breakdown, Tony Brueski teams up with retired FBI Special Agent Robin Dreeke and defense attorney Bob Motta (Defense Diaries) to dissect the chilling implications of the so-called “Amazon Evidence.” If true, this isn't just forensic coincidence — it's a psychological signature. Dreeke dives into what these purchases reveal about a possible obsessive, methodical mindset: someone fascinated by control, process, and precision. But in his precision, perhaps also arrogant — believing intellect could outsmart technology. Then, Motta joins Tony to examine how this alleged evidence fits into the broader defense battle. Could the prosecution argue that Kohberger's shopping habits show premeditation? Or can the defense spin it as circumstantial — just a “collector's curiosity” in military blades? And yes — that infamous thumbs-up shower selfie allegedly taken hours after the murders makes its appearance. Motta and Brueski unpack the surreal combination of vanity, detachment, and potential trophy-taking behavior. It's the kind of moment that would be laughable, if it weren't so horrifying. Together, they explore the haunting question that lingers behind every piece of evidence: Was this a one-time act of obsession, or a rehearsal for something darker?

Santa, baby! We're here to deliver the #damngood gifts of the season that the beauty lover on your list will *actually* want - no snoozefest presents in sight. Watch, and subscribe to this episode on YouTube! You'll hear about:The makeup musts we're swooning over (a luxury blush trio, lip gloss “stacks,” and a palette fit for Celine Dion)A makeup-meets-indie jewellery collab that's sure to spark conversation at any holiday party A chic AF bar soap gift set that's giving us major flashbacks to a coveted childhood stocking stufferThe high quality hair clips that not only hold up the thickest hair, but that are also the hottest style accessory of the season A French-girl approved advent calendar that doesn't skimp out on beauty goodiesA limited edition version of a 100-year old fragrance that's been updated for the vanilla lover on your list! (And the insider tip for how you can personalize it.) One of the most-searched for beauty gifts of the season, revealed (this one might surprise you!) Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Related episodes like this: Shop Smarter, Not Harder – How-to Get Real Value from Your Beauty Buys

This month, the gals bless us with their long-time bestie, the famous Blortney! Topics include guinea pig parties, overturned monkeys, a poopy pants puzzle, and eyebrow innovation. Don't be a stinker and a meanie, tune in for November's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.

CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient’s own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartnerSee omnystudio.com/listener for privacy information.